BR0116377A - Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria - Google Patents

Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria

Info

Publication number
BR0116377A
BR0116377A BR0116377-9A BR0116377A BR0116377A BR 0116377 A BR0116377 A BR 0116377A BR 0116377 A BR0116377 A BR 0116377A BR 0116377 A BR0116377 A BR 0116377A
Authority
BR
Brazil
Prior art keywords
preparing
pharmaceutically active
suspension
active compound
submicronically
Prior art date
Application number
BR0116377-9A
Other languages
English (en)
Inventor
James E Kipp
Joseph Chung Tak Wong
Mark J Doty
Christine L Rebbeck
Sean Brynjelsen
Jane Werling
Ajaram Sriram
Original Assignee
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,637 external-priority patent/US6869617B2/en
Priority claimed from US09/953,979 external-priority patent/US6951656B2/en
Priority claimed from US10/035,821 external-priority patent/US6977085B2/en
Priority claimed from US10/021,692 external-priority patent/US6884436B2/en
Application filed by Baxter Int filed Critical Baxter Int
Publication of BR0116377A publication Critical patent/BR0116377A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)

Abstract

"MéTODOS PARA PREPARAR PARTìCULAS SUBMICRONICAMENTE DIMENSIONADAS DE UM COMPOSTO ORGâNICO, E PARA PREPARAR UMA SUSPENSãO DE UM COMPOSTO FARMACEUTICAMENTE ATIVO, E, COMPOSIçãO DE MATERIAL". A presente invenção provê um método para preparar uma suspensão de um composto farmaceuticamente ativo, cuja solubilidade é maior em um primeiro solvente orgânico miscível em água do que em um segundo solvente que é aquoso. O processo inclui as etapas de: (i) dissolver uma primeira quantidade do composto farmaceuticamente ativo no primeiro solvente orgânico miscível em água, para formar uma primeira solução; (ii) misturar a primeira solução com o segundo solvente, para precipitar o composto farmaceuticamente ativo; e (iii) semear a primeira solução ou o segundo solvente ou a suspensão.
BR0116377-9A 2000-12-22 2001-12-20 Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria BR0116377A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US25816000P 2000-12-22 2000-12-22
US09/874,637 US6869617B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,799 US6607784B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/874,499 US7037528B2 (en) 2000-12-22 2001-06-05 Microprecipitation method for preparing submicron suspensions
US09/953,979 US6951656B2 (en) 2000-12-22 2001-09-17 Microprecipitation method for preparing submicron suspensions
US10/035,821 US6977085B2 (en) 2000-12-22 2001-10-19 Method for preparing submicron suspensions with polymorph control
US10/021,692 US6884436B2 (en) 2000-12-22 2001-12-12 Method for preparing submicron particle suspensions
PCT/US2001/049737 WO2002055059A2 (en) 2000-12-22 2001-12-20 Method for preparing submicron particle suspensions

Publications (1)

Publication Number Publication Date
BR0116377A true BR0116377A (pt) 2005-12-13

Family

ID=27567644

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116377-9A BR0116377A (pt) 2000-12-22 2001-12-20 Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria

Country Status (16)

Country Link
EP (2) EP1642571A3 (pt)
JP (1) JP4376518B2 (pt)
CN (1) CN100512798C (pt)
AT (1) ATE319432T1 (pt)
AU (2) AU2002249836B2 (pt)
BR (1) BR0116377A (pt)
CA (1) CA2431705C (pt)
DE (1) DE60117873T2 (pt)
DK (1) DK1347747T3 (pt)
ES (1) ES2260337T3 (pt)
HU (1) HUP0501030A3 (pt)
IL (1) IL156310A0 (pt)
MX (1) MXPA03005496A (pt)
NO (1) NO20032860L (pt)
NZ (1) NZ526608A (pt)
WO (1) WO2002055059A2 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
MXPA04002446A (es) 2001-09-26 2004-07-23 Baxter Int Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente.
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
US20040028747A1 (en) * 2002-08-06 2004-02-12 Tucker Christopher J. Crystalline drug particles prepared using a controlled precipitation process
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7511079B2 (en) * 2003-03-24 2009-03-31 Baxter International Inc. Methods and apparatuses for the comminution and stabilization of small particles
BRPI0409929A (pt) * 2003-04-29 2006-04-25 Baxter Int formulação para tornar uma droga antimicrobiana potente contra organismos normalmente considerados serem resistentes à droga
US8986736B2 (en) 2003-06-24 2015-03-24 Baxter International Inc. Method for delivering particulate drugs to tissues
US9044381B2 (en) 2003-06-24 2015-06-02 Baxter International Inc. Method for delivering drugs to the brain
JP2007531701A (ja) * 2003-07-18 2007-11-08 バクスター・インターナショナル・インコーポレイテッド 制御された相分離により調製される小球状粒子の作製方法、使用および組成物
JPWO2005013938A1 (ja) * 2003-08-06 2006-09-28 エーザイ株式会社 薬物超微粒子の製造法及び製造装置
GB0327390D0 (en) * 2003-11-25 2003-12-31 Pfizer Ltd Pharmaceutical formulations
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
US20050202094A1 (en) * 2004-01-29 2005-09-15 Werling Jane O. Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
PL1731138T3 (pl) * 2004-03-31 2016-10-31 Drobnoziarnista dyspersja słabo rozpuszczalnego leku i sposób jej wytwarzania
BRPI0510271A (pt) 2004-06-15 2007-10-30 Baxter Int aplicações ex-vivo agentes terapêuticos microparticulados
DE102004031538A1 (de) * 2004-06-29 2006-02-09 Baxter International Inc., Deerfield Pharmazeutische Darreichungsform zur oralen Verabreichung eines schwerlöslichen Wirkstoffs, Verfahren zu deren Herstellung und Kit
CA2590675A1 (en) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Nanoparticulate tacrolimus formulations
EP1868576A2 (en) * 2005-03-17 2007-12-26 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
DE102005053862A1 (de) * 2005-11-04 2007-05-10 Pharmasol Gmbh Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
BRPI0618661A2 (pt) * 2005-11-15 2011-09-06 Baxter Int composições de inibidores de lipoxigenase
CN101965195A (zh) 2008-03-05 2011-02-02 巴克斯特国际公司 用于药物投送的组合物和方法
DE102009008478A1 (de) 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
US10952965B2 (en) 2009-05-15 2021-03-23 Baxter International Inc. Compositions and methods for drug delivery
EA025562B1 (ru) 2010-03-22 2017-01-30 Инстилло Гмбх Способ для получения микрочастиц или наночастиц и устройство для его осуществления
CN102384973B (zh) * 2011-08-10 2014-09-10 华南理工大学 快速定量检测羟甲基糠醛的免疫层析试纸条及其制备方法
CN102268103B (zh) * 2011-09-02 2013-06-05 中国海洋大学 一种壳聚糖醋酸盐的制备方法
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
CN103212079A (zh) * 2013-04-26 2013-07-24 陆媛 一种预防和/或治疗感冒的含服药物组合物及其应用
CN104905262B (zh) * 2015-05-29 2017-12-22 湖北省农业科学院农产品加工与核农技术研究所 一种制备虫草灵芝复合制剂的方法
KR101725508B1 (ko) * 2015-07-31 2017-04-11 국방과학연구소 헥사나이트로스틸벤 입자의 제조 방법과 그 장치
CN105969316B (zh) * 2016-06-03 2020-11-10 宁海德宝立新材料有限公司 一种用于热敷的相变储热复合材料
CA3030308C (en) 2016-07-29 2022-04-05 The Board Of Trustees Of Western Michigan University Magnetic nanoparticle-based gyroscopic sensor
CN108031142A (zh) * 2017-12-13 2018-05-15 上海合全药物研发有限公司 一种简化的利用湿磨来制备大量微晶种的装置及方法
CN115349630A (zh) * 2022-06-20 2022-11-18 海宁凤鸣叶绿素有限公司 水分散性叶黄素微囊粉的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
CA1282405C (en) * 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
US4606940A (en) * 1984-12-21 1986-08-19 The Ohio State University Research Foundation Small particle formation and encapsulation
FR2634397B2 (fr) * 1986-12-31 1991-04-19 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules
FR2608988B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules
IL86211A (en) * 1987-05-04 1992-03-29 Ciba Geigy Ag Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
GB9413202D0 (en) * 1994-06-30 1994-08-24 Univ Bradford Method and apparatus for the formation of particles
SE9403846D0 (sv) * 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
FI973804A (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
WO1999033467A1 (en) * 1997-12-31 1999-07-08 Choongwae Pharma Corporation Method and composition of an oral preparation of itraconazole
CN1245955C (zh) * 1998-05-29 2006-03-22 斯凯伊药品加拿大公司 热保护微粒组合物及其最终蒸汽灭菌的方法
BR9906712A (pt) * 1998-07-17 2000-10-10 Janssen Pharmaceutica Nv Péletes que apresentam um núcleo revestido com um antifúngico e um polìmero
DK1163234T3 (da) * 1999-03-24 2006-02-27 Scherer Technologies Inc R P Farmaceutiske formuleringer med forbedret vandoplöselighed
KR100331529B1 (ko) * 1999-06-16 2002-04-06 민경윤 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법

Also Published As

Publication number Publication date
CA2431705A1 (en) 2002-07-18
MXPA03005496A (es) 2004-05-14
NO20032860D0 (no) 2003-06-20
AU2006201943A1 (en) 2006-06-01
EP1642571A3 (en) 2007-06-27
CA2431705C (en) 2010-10-05
NO20032860L (no) 2003-08-21
ATE319432T1 (de) 2006-03-15
WO2002055059A2 (en) 2002-07-18
DE60117873T2 (de) 2006-08-24
IL156310A0 (en) 2004-01-04
DE60117873D1 (de) 2006-05-04
JP2004538249A (ja) 2004-12-24
WO2002055059A3 (en) 2002-09-06
AU2002249836B2 (en) 2006-12-14
HUP0501030A2 (en) 2007-02-28
EP1642571A2 (en) 2006-04-05
CN100512798C (zh) 2009-07-15
ES2260337T3 (es) 2006-11-01
CN1505503A (zh) 2004-06-16
JP4376518B2 (ja) 2009-12-02
HUP0501030A3 (en) 2008-04-28
EP1347747A2 (en) 2003-10-01
EP1347747B1 (en) 2006-03-08
DK1347747T3 (da) 2006-04-10
NZ526608A (en) 2006-06-30

Similar Documents

Publication Publication Date Title
BR0116377A (pt) Métodos para preparar partìculas submicronicamente dimensionadas de um composto orgânico, e para preparar uma suspensão de um composto farmaceuticamente ativo, e, composição de matéria
BR9509720A (pt) Processo para a preparação de pequenas partículas compreendendo um composto orgânico cuja solubilidade é maior em um primerio solvente miscível em água que em um segundo solvente que é aquoso e uso das pequenas partículas
BR0103844A (pt) Sistema de aditivo polimérico múltiplo, processo para produzir o mesmo, composição polimérica, e, processo para produzir a mesma
BR0210867A (pt) Processo para a preparação de um material particulado, métodos para aglomeração controlada de um material sólido finamente disperso, para melhorar a biodisponibilidade de uma substância terapêutica e/ou profilaticamente ativa, e para melhorar a vida em prateleira de uma composição farmacêutica, material articulado, composição farmacêutica, uso de um veìculo, material particulado farmacêutico, e, uso de aluminossilicato de magnésio e/ou de aluminometassilicato de magnésio
PT1389089E (pt) Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
RU94045798A (ru) Стереоизомеры итраконазола или саперконазола, способ их получения, их комплексы и способ получения, фармацевтическая композиция на их основе и ее получение, способ получения водных растворов с повышенной концентрацией итраконазола или саперконазола
BR0212833A (pt) Preparação de nanopartìculas de tamanho submìcron através de dispersão e de remoção de solvente ou de fase lìquida
ES2178268T3 (es) Formulaciones de liberacion controlada.
BR0211705A (pt) Processo para a preparação de uma dispersão estável de partìculas sólidas em um meio aquoso, dispersão estável aquosa, partìcula sólida, composição farmacêutica, método para a inibição do amadurecimento de ostwald em uma dispersão de partìculas sólidas substancialmente insolúveis em água em um meio aquoso, e, uso de um inibidor
CO5580735A2 (es) Composicion para el tratamiento del cabello que comprende particulas compuestas de arcilla y una molecula organica cargada
BRPI0215331B8 (pt) composições aquosas contendo metronidazol
PT99445A (pt) Processo para preparacao de derivados do 1,4,7,10-tetraazaciclododecano mono-n--substituidos e de composicoes farmaceuticas que os contem
BR0012434A (pt) Composto, processo para a preparação do mesmo, uso de um composto, composição farmacêutica.
BR9913433A (pt) Sistema desinfetante estabilizado composto de duas partes e composições e métodos a ele relacionado
BRPI0413957A (pt) processo para preparar diterpenos solúveis em água, solução aquosa e suas aplicações
BR0011738A (pt) Derivados de benzeno, processo para a preparação dos mesmos e composições farmacêuticas que os contêm
BR0008339A (pt) Sol orgânico, composto sólido, processo de preparação de um sol, e utilização do mesmo
BRPI0410772A (pt) tratamento de resinas para diminuir os nìveis de espécies produtoras de cpd e melhorar a estabilidade de gelação
BRPI0411500A (pt) pesticida para aplicar um aniquilamento de modo de ação fìsica, composição hidrocoloidal, método de aniquilamento de pestes em plantas pelo modo fìsico de operação e processo para a preparação de um pesticida
BRPI0416479A (pt) derivado quinazolina, composição farmacêutica, e, processo para a preparação de um derivado de quinazolina
PT801559E (pt) Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
BR9916591A (pt) Processo para produzir um aminoácido ácidon-acilado de cadeia longa, aminoácido ácidon-acilado de cadeia longa ou um sal do mesmo,composição cosmética lìquida ou sólida, e,composição detergente
BR0209935A (pt) Processo para remover seletivamente molibdênio de misturas lìquidas contendo o mesmo
BR0008341A (pt) Sol orgânico, composto sólido, processo de preração de um sol, e, utilização de um sol
MX170537B (es) Aducto antitranspirante submicronico y proceso para su preparacion

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/10, A61K 31/496, A61P 31/00

Ipc: A61K 9/10 (2011.01), A61K 31/496 (2011.01), A61P 3

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 10A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.